Trials / Completed
CompletedNCT00681395
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-143 | once daily for 6 days |
| DRUG | ABT-335 | once daily for six days |
| DRUG | Rosuvastatin | Once daily for 6 days |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2008-08-01
- First posted
- 2008-05-21
- Last updated
- 2012-09-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00681395. Inclusion in this directory is not an endorsement.